碳酸司维拉姆起始治疗与透析患者死亡率的关系
该研究基于DOPPS 3-4期(2005-2011)12564例已使用钙基磷结合剂的血液透析患者,其中2606例后续加用或换用司维拉姆。采用序贯分层匹配分析显示,司维拉姆治疗与死亡风险降低14%相关(HR 0.86,95%CI 0.76-0.97),提示其作为加用或替代治疗可能改善生存。
要点
- 在已用钙基磷结合剂的透析患者中,起始司维拉姆与死亡风险降低14%相关(HR 0.86, 95%CI 0.76-0.97)。
- 司维拉姆治疗前4个月平均血磷下降0.3 mg/dl,之后逐渐下降。
- 敏感性分析(改变匹配卡钳值、治疗与未治疗比例、倾向性评分匹配)结果一致。
核心结论
- 在维持性血液透析且已使用钙基磷结合剂的患者中,起始司维拉姆(加用或替代)与改善生存相关。
研究设计与样本
- 基于DOPPS 3期和4期(2005-2011年)的前瞻性队列研究,纳入12564例基线或司维拉姆治疗前已处方钙基磷结合剂的患者。
- 采用序贯分层方法,将新接受司维拉姆治疗的患者与尚未治疗且死亡风险匹配的患者进行比较。
主要发现
- 12564例患者中2606例后续接受司维拉姆(盐酸盐或碳酸盐)治疗。
- 开始司维拉姆治疗后,前4个月平均血磷水平下降0.3 mg/dl,之后逐渐下降。
- 匹配2501例治疗患者与至少1例尚未治疗患者,司维拉姆治疗组死亡风险降低14%(HR 0.86,95%CI 0.76-0.97)。
- 敏感性分析(改变匹配卡钳值、治疗与未治疗比例、倾向性评分匹配)结果相似。
关键数值与推荐
- 司维拉姆起始治疗与死亡风险降低相关:HR 0.86(95%CI 0.76-0.97)。
- 治疗前4个月平均血磷下降0.3 mg/dl。
临床怎么用
- 对于已使用钙基磷结合剂的血液透析患者,可考虑加用或换用司维拉姆以改善生存。
- 司维拉姆治疗期间需监测血磷变化,前4个月平均下降约0.3 mg/dl。
局限性
- 研究为观察性设计,可能存在残余混杂。
- 仅纳入DOPPS 3-4期(2005-2011)数据,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Prior studies have shown that sevelamer attenuates progression of arterial calcification and may reduce the risk of death compared with calcium-based phosphate binders. In clinical practice, however, sevelamer is used not only as an alternative but also as an add-on therapy in patients already being treated with calcium-based phosphate binders. We analyzed the Dialysis Outcomes and Practice Patterns Study (DOPPS) data to test the hypothesis that the initiation of sevelamer is associated with improved survival in patients on hemodialysis treated with calcium-based phosphate binders. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We included 12,564 patients from DOPPS phase 3 and phase 4 (2005-2011) who were prescribed calcium-based phosphate binders at baseline or before sevelamer treatment. Mortality risk was assessed using a sequential stratification method to identify as-yet-untreated patients who were appropriately matched to the newly treated patients on the basis of their risk of death. RESULTS: Of 12,564 patients, 2606 were subsequently treated with sevelamer hydrochloride or sevelamer carbonate. After beginning sevelamer therapy, mean serum phosphorus levels decreased by 0.3 mg/dl in the first 4 months and gradually decreased thereafter. We matched 2501 treated patients with at least one as-yet-untreated patient. Patients treated with sevelamer had a 14% lower risk for mortality compared with as-yet-untreated patients (hazard ratio, 0.86; 95% confidence interval, 0.76 to 0.97). Similar results were observed in the sensitivity analyses when changing the matching calipers or the treated and as-yet-untreated ratios, and by using propensity score matching. CONCLUSIONS: The use of sevelamer as an add-on or alternative therapy to calcium-based phosphate binders is associated with improved survival in patients on maintenance hemodialysis.
引用
- Komaba H, Wang M, Taniguchi M, et al. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders. Clin J Am Soc Nephrol. 2017. PMID: 28724618. doi:10.2215/CJN.13091216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。